Pramipexole Dihydrochloride

  • #LGM Pharma is a Pramipexole Dihydrochloride CAS# 104632-25-9 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 104632-25-9
  • AHFC code: 28:36.20.08
  • Synonyms: Mirapex, Mirapex ER, Pramipexole dihydrochloride, Pramipexole HCl, Pramipexole hydrochloride, UNII-4R2HD0M28N
  • ATC Code: N04BC05
  • Chemical Formula: C10-H17-N3-S.2Cl-H
  • Molecular Weight: 284.2531
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00413 (APRD00156)
  • SMILES: Cl.Cl.c12c(C[C,H](CC2)NCCC)sc(n1)N
  • InChl: 1S/C10H17N3S.2ClH/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;/h7,12H,2-6H2,1H3,(H2,11,13);2*1H/t7-;;/m0../s1
  • PubChem: 119570
  • IUPAC: 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, dihydrochloride, (6S)- 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, dihydrochloride, (S)-

Additional Details

Indication:
For the treatment of signs and symptoms of idiopathic Parkinson’s disease
Pharmacodynamics:
Pramipexole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson’s disease is unknown. The precise mechanism of action of Pramipexole as a treatment for Parkinson’s disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that Pramipexole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum.
Mode of Action:
The precise mechanism of action of Pramipexole as a treatment for Parkinson’s disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum.
Metabolism:
No metabolites have been identified in plasma or urine.
Toxicity:
General Reference:
Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM: Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 1995 Jun 23;290(1):29-36. [PubMed:7664822
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos